JPRN-UMIN000027873已完成未知
Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with Nivolumab - Serum soluble PD-L1 and nibolumab in patients with renal cell carcinoma
Kobe University Graduate School of Medicine0 个研究点目标入组 48 人开始时间: 2017年9月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •History with other malignancies Pregnant
研究者
相似试验
已完成
2 期
Predictive efficacy of serum soluble PD-L1 on patients with metastatic renal cell carcinoma treated with niivolumabrenal cell carcinoma, kidney cancerrenal cell carcinomaJPRN-jRCTs051180092akano Yuzo43
已完成
不适用
Predictive Impact of PD-L1 expression for anti-tumor activity of osimertinib in patients with T790M mutated non-small cell lung cancernon-small cell lung cancer harboring EGFR-T790M mutation after treatment with EGFR-TKIJPRN-UMIN0000268182nd division, Department of internal medicine, Hamamatsu University School of Medicine46
招募中
不适用
Exosomal PD-L1 Level in plasma as a predictive marker for diagnosis and clinical correlation in non-small cell lung canceron small cell lung cancerBiomarkerExosomeliquid biopsypathologyPD-LNon-small cell lung cancerTCTR20210808001Chulalongkorn University Systems biology center70
Unknown
不适用
Effect of Chemotherapy on PD-L1 in NSCLCChemotherapyImmunotherapyPD-L1NCT03701607Baodong Qin30
已完成
不适用
A retrospective study to investigate PD-L1 expression before and after EGFR-TKI therapy and its relationship with EGFR-TKI resistance mechanism in EGFR mutation-positive advanced recurrent non- squamous non-small-cell lung cancerEGFR mutation-positive advanced recurrent non-squamous non-small-cell lung cancerJPRN-UMIN000033993Kindai university, Faculty of Medicine, Department of Medical Oncology80